[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Pallotta et al. - Google Patents

P0496 MUSCULAR INFLAMMATORY STATE AND PHENOTYPIC SWITCH IN DIVERTICULOSIS AND COMPLICATED DIVERTICULAR DISEASE

Pallotta et al.

View PDF
Document ID
12461989310581563654
Author
Pallotta L
Scirocco A
Ignazzi A
Maselli M
Carabotti M
Cicenia A
Severi C
Publication venue
25th United European Gastroenterology Week Barcelona 2017

External Links

Snippet

Aims & Methods: Aim of this study was to determine, both in human uninvolved and involved tracts of asymptomatic diverticulosis (ADÀ, ADþ) and in stenotic segments of complicated diverticular disease (CDD), the alterations intrinsic to smooth muscle. Circular and …
Continue reading at www.bib.irb.hr:8443 (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids

Similar Documents

Publication Publication Date Title
Homma et al. Clinical guidelines for interstitial cystitis/bladder pain syndrome
Conteduca et al. Barrett's esophagus and esophageal cancer: an overview
Conteduca et al. H. pylori infection and gastric cancer: state of the art
Zagari et al. Epidemiology of functional dyspepsia and subgroups in the Italian general population: an endoscopic study
Mao et al. A pilot study of a grape seed procyanidin extract for lung cancer chemoprevention
Chen et al. H. pylori‐induced NF‐κB‐PIEZO1‐YAP1‐CTGF axis drives gastric cancer progression and cancer‐associated fibroblast‐mediated tumour microenvironment remodelling
Bowen et al. Combination of sulindac and bexarotene for prevention of intestinal carcinogenesis in familial adenomatous polyposis
Ni et al. The nerve-tumour regulatory axis GDNF-GFRA1 promotes tumour dormancy, imatinib resistance and local recurrence of gastrointestinal stromal tumours by achieving autophagic flux
Zhang et al. A comparative study of vestibular improvement and gastrointestinal effect of betahistine and gastrodin in mice
Chwiesko et al. Perspectives on the interlinked nature of systemic sclerosis and reflux disease
Arora et al. Risk factors for Barrett's esophagus
Pallotta et al. P0496 MUSCULAR INFLAMMATORY STATE AND PHENOTYPIC SWITCH IN DIVERTICULOSIS AND COMPLICATED DIVERTICULAR DISEASE
Yalçin et al. The association of adrenocortical carcinoma and thyroid cancer in a child with Peutz-Jeghers syndrome
Furuta Emerging questions regarding eosinophil's role in the esophago-gastrointestinal tract
Kim Esophageal Diseases
Spechler et al. Barrett esophagus and esophageal adenocarcinoma
Lower Lower GI
Jin et al. Precision therapy for cancer prevention by targeting carcinogenesis
Gomaa et al. SOX9 is regulated by AURKA in response to Helicobacter pylori infection via EIF4E-mediated cap-dependent translation
Chia et al. SUPPLEMENT ARTICLE
Geeraerts et al. P. Nafteux3, H. Van Veer3, T. Vanuytsel4, J. Tack5 1University of Leuven, Translational Research Center for Gastrointestinal Disorders, Leuven, Belgium, 2UZLeuven, Gastroenterology, Leuven, Belgium, 3University of Leuven
Yang et al. CSTA: A Biomarker Regulating Esophageal Stricture Epithelial Barrier, Potential Medication Target
Quigley et al. Barrett's esophagus: clinical features, obesity, and imaging
Löhr et al. 42nd European Pancreatic Club (EPC) Meeting
Guo et al. Published Only